Sponsors Talk AI: Sanofi's Take On The Evolving Role Of AI In Clinical Trials

Artificial intelligence is moving beyond pilot programs and into the core of clinical research operations. In a recent AI in Business podcast hosted by Emerj, Matthew Peruhakal, Global Head of Data Architecture, Utilization, and AI Engineering at Sanofi, shared how one of the world’s largest pharmaceutical companies is embedding AI to transform the clinical trial process.

Peruhakal outlined a shift from simple digitization — like replacing paper forms with eConsent — to intelligent data orchestration, where structured and unstructured information connect seamlessly to guide real-time decision-making. This evolution is redefining how clinical data is managed, analyzed, and applied, from protocol design and safety monitoring to regulatory submissions.

Central to Sanofi’s approach are three strategic pillars: a modern, unified data architecture; document intelligence that extracts insights from global content; and interoperability that bridges data silos to power automation. Together, these enable proactive, intelligent workflows capable of identifying risks early and optimizing operations at scale.

Beyond technology, Peruhakal emphasized culture, trust, and accessibility, and how ensuring AI empowers, rather than replaces, human expertise. His perspective offers a glimpse into how leading life sciences organizations are weaving AI into their operational DNA.

Explore how intelligent systems are reshaping the future of clinical trials and data-driven innovation.